news
Macrophage-mediated phagocytosis: treating solid tumours
A new immunotherapy approach combining co-engineered T cells and antibodies enhances phagocytosis of tumour cells.
List view / Grid view
T cells
article
Treating immune-mediated diseases with nanoparticles
In this Q&A, we had the privilege of speaking to COUR Pharmaceuticals’ CEO John Puisis. He offers insights into how their innovative immune-modifying nanoparticle platform differs from traditional approaches for treating immune-mediated diseases.
article
Improving treatment responses to solid tumours with trispecific TCEs
Following Zymeworks’ presentation at AACR 2024, in this Q&A, Dr Nina Weisser explains how the next generation trispecific T cell engager platform with integrated CD28 costimulation is engineered to tackle solid tumours.
article
Utilising engineered peptides for immunotherapy
In this Q&A, Dr DaeYong Lee discusses how a new method for building up natural immune response could lead to new immunotherapy drugs with safer toxicity profiles.
news
New TEC organoid model to study thymus function
The new organoids demonstrate a greater diversity of TECs in culture and are capable of maturing T cells.
news
How tumours prevent formation of immune responses
Scientists found that preventing the effects of prostaglandin E2 could be an effective therapy to overcome tumour defence.
news
Explaining uveal melanoma’s resistance to conventional immunotherapies
Researchers have developed a new tool called ‘Uveal Melanoma Immunogenic Score’ to predict which patients will respond to adoptive therapy.
news
FOXO1 improves survival and function of CAR T cells
Evidence indicating that FOXO1 plays a unique role in promoting T cell longevity could result in more effective CAR T cell therapies.
news
Eliminating the HIV virus from infected cells with CRISPR-Cas
The proof-of-concept study could lead to a cure for HIV that inactivates diverse strains across multiple cellular contexts.
news
New insights about the influence of STAP-1 on immune cell activation
The new findings could lead to a therapeutic target for immune-related disorders, like multiple sclerosis.
news
New insights into PD-1 formation could greatly improve treatments
A single change in the amino acid structure of the transmembrane segment can either enhance or diminish the inhibitory function of PD-1 in immune responses.
news
How successive mRNA vaccines shape T-cell memory
A new study shows that changes in clonal dominance characterises T-cell memory against multiple COVID-19 variants following mRNA vaccinations.
article
Gamma delta T cells: a rising star in cancer therapy
Gamma delta (γδ) T cells comprise a distinct and powerful subpopulation of T cells, bridging innate and adaptive immunity, that holds great promise for treating cancer. IN8Bio co-founder and CEO William Ho and COO Kate Rochlin discuss what makes γδ T cells unique, how preclinical research suggests their antitumour activity…
news
New immunological pathway to treat bone tumours
Researchers observed significant upregulation of Siglec-15 in the tumour microenvironment in bone tumour samples from breast cancer patients.
news
How PD-1 promotes Merkel cell carcinoma progression
Inhibiting mTOR signalling and neutralising mtROS suppressed MCC-PD-1-mediated tumour proliferation in mice.
